These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32379358)

  • 41. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Mattoo VY; Basnayake C; Connell WR; Ding N; Kamm MA; Lust M; Niewiadomski O; Thompson A; Wright EK
    Aliment Pharmacol Ther; 2021 Aug; 54(3):249-266. PubMed ID: 34153124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Greener T; Boland K; Milgrom R; Ben-Bassat O; Steinhart AH; Silverberg MS; Narula N
    Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1274-1279. PubMed ID: 34402466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
    Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease.
    Qiu Y; Chen BL; Mao R; Zhang SH; He Y; Zeng ZR; Ben-Horin S; Chen MH
    J Gastroenterol; 2017 May; 52(5):535-554. PubMed ID: 28275925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
    Suzuki Y; Matsui T; Ito H; Ashida T; Nakamura S; Motoya S; Matsumoto T; Sato N; Ozaki K; Watanabe M; Hibi T
    Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
    Ding NS; McDonald JAK; Perdones-Montero A; Rees DN; Adegbola SO; Misra R; Hendy P; Penez L; Marchesi JR; Holmes E; Sarafian MH; Hart AL
    J Crohns Colitis; 2020 Sep; 14(8):1090-1102. PubMed ID: 32119090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
    Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M
    Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
    Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
    J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2024 Apr; 18(4):642-658. PubMed ID: 37943286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
    Bouhnik Y; Carbonnel F; Laharie D; Stefanescu C; Hébuterne X; Abitbol V; Nachury M; Brixi H; Bourreille A; Picon L; Bourrier A; Allez M; Peyrin-Biroulet L; Moreau J; Savoye G; Fumery M; Nancey S; Roblin X; Altwegg R; Bouguen G; Bommelaer G; Danese S; Louis E; Zappa M; Mary JY;
    Gut; 2018 Jan; 67(1):53-60. PubMed ID: 28119352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of medical therapy on patients with Crohn's disease requiring surgical resection.
    Fu YT; Hong T; Round A; Bressler B
    World J Gastroenterol; 2014 Sep; 20(33):11808-14. PubMed ID: 25206286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study.
    Attar A; Duru G; Roblin X; Savarieau B; Brunel P; Lamure M; Peyrin-Biroulet L
    Dig Liver Dis; 2019 Jan; 51(1):112-119. PubMed ID: 30268737
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
    Papamichael K; Cheifetz AS
    World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
    Bhalme M; Sharma A; Keld R; Willert R; Campbell S
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
    Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
    Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.